Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + toripalimab perioperative treatment for HER2-expressing muscle-invasive bladder cancer
CTR20220425Phase 2Active
- Sponsor
- RemeGen
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in bladder cancer and transitional cell carcinoma (TCC), sponsored by RemeGen. Started May 2022; status: active.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20220425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220425.